Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Xarelto Bellwether Trials Expected to Begin in August 2016 For Bleeding Lawsuits June 25, 2015 Austin Kirk Add Your Comments The U.S. District Judge presiding over all federal Xarelto bleeding lawsuits has indicated a series of bellwether trials in the federal multidistrict litigation (MDL) may begin by August 2016. For the past six months, all product liability complaints filed throughout the federal court system involving bleeding problems with Xarelto have been consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana to reduce duplicative discovery into common issues in the cases, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts. There are currently at least 552 bleeding lawsuits pending in the Xarelto MDL, which all involve similar allegations that the drug makers failed to provide adequate warnings about the potential side effects of Xarelto. Learn More About Xarelto Lawsuits Side Effects of Xarelto May Increase Risk of Uncontrollable Bleeding. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Xarelto Lawsuits Side Effects of Xarelto May Increase Risk of Uncontrollable Bleeding. Learn More SEE IF YOU QUALIFY FOR COMPENSATION As a growing number of complaints continue to be filed, Judge Fallon has indicated that a small group of “bellwether” cases will be selected for early trial dates. While the outcomes of these trials are not binding on other cases, they are designed to to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation and may facilitate eventual Xarelto settlements. According to a Minute Entry (PDF) issued following a status conference on June 22, Judge Fallon has proposed that 40 plaintiffs be selected for a “pool” of bellwether cases, which will go through case-specific discovery in preparation for a series of trials that are expected to begin late next year. The potential discovery and trial schedule discussed by Judge Fallon calls for the first Xarelto trial to begin on August 1, 2016, followed by a second trial on August 22, 2016, a third trial on September 12, 2016, and the fourth trial on October 17, 2016. The Court has suggested that the first two trials would take place in the Eastern District of Louisiana, the third trial would take place in the Southern District of Texas, and the fourth trial would take place in the Southern District of Mississippi. The conference came following a Xarelto “Science Day” held by Judge Fallon earlier this month, which allowed both sides to present information to the Court in a non-adversarial manner about the medical and scientific issues that will come up throughout the bleeding lawsuits. Xarelto Bleeding Problems Xarelto (rivaroxoaban) was introduced in 2011 as a superior replacement for Coumadin (warfarin), designed to reduce the risk of blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism. Since it hit the market, the drug has been aggressively marketed and has quickly grown to become one of the top selling medications in the United States. While all blood thinners carry a risk of bleeding injury, Xarelto has been linked to a surprising number of problems involving severe and uncontrollable bleeds, sometimes resulting in death.. Xarelto has been promoted as easier to use than warfarin, since it does not require regular blood monitoring. However, several recent studies have raised questions about those claims, with researchers suggesting that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding. In addition to failing to warn about the risk of bleeding and importance of blood monitoring, plaintiffs pursuing bleeding claims allege that the drug makers withheld information about the lack of a Xarelto reversal agent, which doctors could use to stop hemorrhaging that may develop among users. While warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto. Similar allegations were raised in the litigation over Pradaxa, which is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010, one year before Xarelto hit the market. More than 4,000 Pradaxa lawsuits were filed by users of that drug who suffered bleeding injuries. Following several years of litigation, Boehringer Ingelheim ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. Tags: Bayer, Bleeding, Blood Thinner, Johnson & Johnson, Pradaxa, Xarelto More Xarelto Lawsuit Stories Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024 Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022 Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)